Key Points
- Insider sale: Andreas Wagner sold 22,238 shares at an average price of $20.47 for a total of $455,211.86, cutting his holding by 11.58% to 169,805 shares.
- Market and ownership context: ALHC trades around $20.39 with a market cap of $4.08 billion (52-week range $11.63–$23.87), and about 86.19% of the stock is held by institutional investors who have recently increased positions, including large buys by Goldman Sachs and RBC.
- Analyst backdrop is mixed but tilted positive: consensus is a “Moderate Buy” with a $23.32 target as several firms raised price targets (Piper Sandler to $30, JPMorgan to $26), while Weiss Ratings still rates it a sell.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) insider Andreas Wagner sold 22,238 shares of Alignment Healthcare stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $20.47, for a total transaction of $455,211.86. Following the sale, the insider directly owned 169,805 shares of the company's stock, valued at $3,475,908.35. This represents a 11.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Alignment Healthcare Stock Down 1.2%
Shares of NASDAQ:ALHC opened at $20.39 on Thursday. The business's 50 day moving average is $20.88 and its 200 day moving average is $17.98. The stock has a market cap of $4.08 billion, a P/E ratio of -169.92, a price-to-earnings-growth ratio of 5.26 and a beta of 1.16. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99.
Institutional Trading of Alignment Healthcare
Hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its position in Alignment Healthcare by 92.6% during the first quarter. Royal Bank of Canada now owns 92,379 shares of the company's stock valued at $1,720,000 after acquiring an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Alignment Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company's stock worth $1,109,000 after purchasing an additional 2,594 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Alignment Healthcare by 79.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company's stock valued at $18,112,000 after purchasing an additional 429,703 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Alignment Healthcare in the 1st quarter worth $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Alignment Healthcare by 16.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company's stock worth $5,729,000 after buying an additional 44,452 shares during the last quarter. 86.19% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on ALHC shares. UBS Group lifted their price objective on Alignment Healthcare from $18.00 to $21.00 and gave the company a "neutral" rating in a report on Wednesday, January 14th. Piper Sandler raised their target price on shares of Alignment Healthcare from $20.00 to $30.00 and gave the company an "overweight" rating in a research report on Tuesday, January 6th. KeyCorp restated an "overweight" rating and issued a $28.00 price target on shares of Alignment Healthcare in a report on Thursday, January 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.32.
Check Out Our Latest Analysis on Alignment Healthcare
About Alignment Healthcare
(
Get Free Report)
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
